Clinicopathologic patterns and treatment outcomes of pediatric classic hodgkin lymphoma in Ethiopian newly opened cancer treatment centers. [PDF]
Worku DT +5 more
europepmc +1 more source
Summary Cytokine release syndrome (CRS) remains a major toxicity of chimeric antigen receptor (CAR) T‐cell therapy in large B‐cell lymphoma (LBCL), and robust pre‐infusion predictors are needed for risk‐adapted management. We retrospectively analysed LBCL patients in the Japanese nationwide registry who underwent CD19 CAR‐T‐cell therapy between 2019 ...
Yasuyuki Arai +21 more
wiley +1 more source
Incidence of Hodgkin and Non-Hodgkin Lymphomas: Comparison of the Military and General Population. [PDF]
Robins KR +4 more
europepmc +1 more source
Summary This prospective study evaluated the incidence and dynamics of frailty in 156 adults with lymphoproliferative syndromes undergoing autologous haematopoietic stem cell transplantation (HSCT). Frailty was assessed using the haematopoietic cell transplantation (HCT) frailty scale in patients from 15 Spanish institutions at initial consultation ...
Javier Cornago +30 more
wiley +1 more source
Autologous bone marrow transplantation in non-Hodgkin lymphoma patients following different conditioning regimens: an 11-year single-center quasi-experimental study. [PDF]
Tavakoli Shiraji S +9 more
europepmc +1 more source
Global, regional, and national burden of lymphoma from 1990 to 2021: a comprehensive analysis based on the global burden of disease study 1990-2021. [PDF]
Shi Y +11 more
europepmc +1 more source
Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown +2 more
wiley +1 more source
Exploring the role of blinatumomab in pediatric B-lymphoblastic lymphoma (B-LLy). [PDF]
Devine KJ, Fries C, Wistinghausen B.
europepmc +1 more source

